The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

ASCO issues recommendations for assessing ovarian toxicity in cancer clinical trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The American Society of Clinical Oncology has released a research statement, “Measuring Ovarian Toxicity in Clinical Trials,” outlining new recommendations for appropriate assessment of ovarian toxicity in cancer clinical trials. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

EC approves of Elahere for treatment of platinum-resistant ovarian cancer

EC granted marketing authorization for Elahere (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens. Elahere is the first and only folate receptor alpha-directed antibody drug conjugate medicine approved in the EU, as well as Iceland, Liechtenstein, Norway, and Northern Ireland.

Climate change exacerbates cancer disparities
Amid disasters, oncologists see urgent need for methodologies, metrics for gauging the problem

Ivan Borrello, medical director of the Myeloma, Bone Marrow Transplant and Cell Therapies Program at Tampa General Hospital’s Cancer Institute, watched as flood waters from Hurricane Helene heaved against a contraption called the AquaFence, which is, as the name suggests, a water-impermeable barrier made of marine-grade laminate and various metals that can withstand storm surges of up to 15 feet above sea level. 
By Claire Marie Porter
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account